Caris Life Sciences, a leading biosciences company focused on fulfilling the promise of precision medicine, today announced a collaboration with GenoSpace, a Massachusetts-based technology company that develops robust software solutions for genomic and health data. Caris will apply GenoSpace's population analytics offerings to uncover and better utilize key insights from the company's industry-leading tumor profiling service, Caris Molecular Intelligence™. The partnership also leverages GenoSpace's analytics architecture expertise to unlock key treatment insights from the Caris Registry™, a database of clinicopathologic and outcome variables from consenting patients whose tumors underwent multi-technology profiling by Caris.
"This collaboration demonstrates our commitment to advancing and improving cancer care through intelligent, targeted and patient-centric research," said David D. Halbert, Chairman and CEO of Caris Life Sciences. "Building on our industry-leading informatics capabilities, our partnership with a company like GenoSpace further establishes our leadership position in providing the highest quality and most clinically actionable tumor profiling information available to physicians and patients today."
With more than 65,000 patients profiled to date, Caris is uniquely positioned to leverage its institutional knowledge and expertise to offer enhanced analysis of its vast tumor profiling databases, in accordance with applicable federal and state laws governing privacy and secondary research. Caris' tumor profiling databases are comprised of multiple assay technologies performed in combination to achieve the most comprehensive molecular profile of a tumor. The resulting analysis and insights, enabled in part by this collaboration, will create a HIPAA-compliant informatics platform that provides Caris' institutional partners the ability to investigate institution-specific profiling data within Caris Molecular Intelligence, expanding and enriching their own research goals. It also allows Caris to more efficiently and expediently isolate novel and/or critical drug-biomarker associations, ultimately providing better treatment information to oncologists and their patients.
"Our collaboration with Caris Life Sciences illustrates our shared passion and commitment to providing precise, actionable information to physicians, their patients and the cancer research community," said John Quackenbush, PhD, CEO of GenoSpace. "The combination of GenoSpace's population analytics offerings and Caris' unprecedented database and registry will provide a unique opportunity for discovery of new biomarkers that can predict a wide range of clinically relevant endpoints and ultimately lead to improvements in the quality and cost of patient care."